Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Invested Capital (2023 - 2025)

Axsome Therapeutics' Return on Invested Capital history spans 3 years, with the latest figure at 0.83% for Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 56.0% year-over-year to 0.83%; the TTM value through Dec 2025 reached 0.83%, up 56.0%, while the annual FY2025 figure was 0.75%, 18.0% up from the prior year.
  • Return on Invested Capital for Q4 2025 was 0.83% at Axsome Therapeutics, up from 1.09% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.57% in Q4 2023 and bottomed at 1.39% in Q4 2024.
  • The 3-year median for Return on Invested Capital is 1.07% (2025), against an average of 1.03%.
  • The largest annual shift saw Return on Invested Capital crashed -82bps in 2024 before it surged 56bps in 2025.
  • A 3-year view of Return on Invested Capital shows it stood at 0.57% in 2023, then crashed by -144bps to 1.39% in 2024, then soared by 40bps to 0.83% in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Return on Invested Capital are 0.83% (Q4 2025), 1.09% (Q3 2025), and 1.07% (Q2 2025).